Dental products company making implants, orthodontics (braces/clear aligners) and diagnostic equipment, spun off from Danaher.
Dental products company making implants, orthodontics (braces/clear aligners) and diagnostic equipment, spun off from Danaher.
Sells dentists implants and orthodontic products, plus equipment and consumables used on every patient, which bring repeat purchases. Many goods reach dental practices through distributors, backed by direct sales and clinician training. Listed in 2019 after being floated out of Danaher.
Moat: narrow (brand, installed base, switching costs). Established dental brands (Nobel Biocare, Ormco) with clinician training and workflow lock-in.
Headquarters: Brea, California · Founded: 2019 · Employees: 12,000
Size Envista (NVST) is a United States Health Care company (Medical Specialties) with a market value of $3.81B, the 1371st largest of 3,085 United States companies the cockpit tracks. Shares closed at $23.75 on 18 Nov 2026.
Performance Over six months the shares fell 0.1%, against +11.1% for the median peer and -2.2% for the United States market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 9.8% over the last twelve months (peer median +5.7%); the operating margin is 11.6% (peer median 12.0%).
Valuation It trades at 14.7× forward earnings against a peer median of 24.4× (cheapest of 20).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -2 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.1 points below its cost of capital (8.5% WACC).
Backlog Backlog (remaining performance obligations) was $173M at 2 Oct 2026, up 9% on a year earlier — 0.1 years of trailing revenue. Backlog detail →
Credit Envista has 1 bond outstanding ($500M), rated Baa3 by the agencies.
Short interest Short interest is 6.1% of the free float (30 Oct 2026).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $2.88B | $2.72B | $2.51B | $2.57B | $2.57B |
| Revenue growth | — | +8% | -2% | 0% | — |
| Gross profit | $1.63B | $1.50B | $1.38B | $1.45B | $1.49B |
| EBITDA | $444M | $361M | $266M | $488M | $533M |
| Net income | $634M | $47.0M | -$1.12B | -$100M | $238M |
| Free cash flow | $242M | $230M | $303M | $218M | $107M |
| Capital expenditure | $59.8M | $45.3M | $33.8M | $58.2M | $75.7M |
| Total debt | $1.59B | $1.60B | $1.55B | $1.65B | $1.53B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Envista NVST | $3.81B | 0% | +10% | 12% | 14.7× | 4.8% |
| Align Technology ALGN | $11.6B | 0% | +4% | 19% | 13.8× | 13.1% |
| DENTSPLY SIRONA XRAY | $1.69B | -13% | -1% | 5% | 6.8× | 11.2% |
| Straumann STMN.SW | $20.4B | +20% | +2% | 21% | 32.9× | 16.2% |
| Henry Schein HSIC | $9.47B | +17% | +6% | 6% | 14.7× | 10.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NVST | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.4% | +5.3% | 10th lowest of 21 |
| 6-month return | -0.1% | +11.1% | 10th lowest of 21 |
| Distance from 52-week high | -21.9% | -24.1% | 10th highest of 21 |
| Revenue growth (TTM) | +9.8% | +5.7% | 9th highest of 21 |
| Operating margin | 11.6% | 12.0% | 10th lowest of 20 |
| Forward P/E | 14.7× | 24.4× | cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | 4.8% | 12.5% | 5th least demanding of 18 |
| Growth delivered (Del g) | +7.1% | +10.0% | 6th lowest of 18 |
| Hurdle (Req g minus delivered) | -2.3 pp | +1.5 pp | 5th least demanding of 18 |
| ROIC minus cost of capital | -1.1 pp | -1.1 pp | 10th highest of 19 |
| EV / EBITDA | 9.5× | 14.0× | 3rd cheapest of 11 |
| Net debt / EBITDA | 1.0× | 1.1× | 6th least indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Envista NVST | United States | $3.81B | 0% | +10% | 12% | 14.7× | 4.8% | +7.1% |
| Andon Health 002432.SZ | China | $3.86B | -24% | -30% | -26% | 16.1× | -6.6% | -7.4% |
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | Germany | $3.73B | +32% | +4% | 15% | 23.0× | 12.7% | +11.0% |
| CareDx CDNA | United States | $3.91B | +252% | +39% | 1% | 50.6× | n/a | n/a |
| Fielmann FIE.DE | Germany | $3.92B | -3% | +3% | 14% | 17.1× | -5.5% | +11.3% |
| Shandong Weigao Blood Purification Products 603014.SS | China | $3.63B | -1% | +4% | n/a | 20.4× | -1.2% | +8.1% |
| Tecan TECN.SW | Switzerland | $3.60B | +59% | -4% | 1% | 35.5× | 45.4% | +3.8% |
| Sumitomo Bakelite 4203.T | Japan | $3.50B | +7% | +15% | 13% | 15.9× | 8.6% | +8.9% |
| Ambu A/S AMBU-B.CO | Denmark | $3.47B | +31% | +7% | 13% | 28.8× | 10.0% | +10.0% |
| Jiangsu Yuyue Medical Equipment & Supply 002223.SZ | China | $4.18B | -3% | -1% | 13% | 20.0× | 4.9% | +3.4% |
| Stevanato STVN | United States | $4.19B | -13% | +12% | 18% | 22.5× | 13.1% | +12.1% |
| Axogen AXGN | United States | $3.40B | +33% | +24% | -5% | 87.3× | 52.6% | +14.9% |
| Pulse Biosciences PLSE | United States | $3.37B | +76% | +1,637% | -5,821% | n/a | n/a | n/a |
| Autobio Diagnostics 603658.SS | China | $3.36B | +16% | +3% | 25% | 20.3× | -0.4% | +7.2% |
| TransMedics TMDX | United States | $3.35B | +42% | +28% | 12% | 43.4× | 38.4% | +88.2% |
| iRay Technology 688301.SS | China | $3.31B | -30% | +58% | 24% | 25.7× | n/a | n/a |
| Zhende Medical 603301.SS | China | $3.26B | -10% | +8% | 7% | 42.5× | 22.9% | -16.1% |
| ICU Medical ICUI | United States | $4.46B | +38% | -6% | 8% | 19.4× | 18.9% | +11.9% |
| Lepu Medical Technology (Beijing) 300003.SZ | China | $3.20B | -13% | -1% | 13% | 24.4× | 8.7% | -4.2% |
| iRhythm IRTC | United States | $3.19B | -19% | +22% | 5% | 99.8× | 46.9% | +23.0% |
| Carl Zeiss Meditec AFX.DE | Germany | $3.17B | +22% | 0% | 8% | 24.4× | 12.5% | +10.8% |
Envista has 1 bond outstanding with $500M face value. The agencies rate it Baa3.
Envista reported $173M of remaining performance obligations at 2 Oct 2026, up 9% from a year earlier and down 2% from the previous quarter. That is 0.1 years of trailing revenue already under contract. Book-to-bill last quarter: 0.99.